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oronary Revascularization
efore Noncardiac
ascular Surgery
ne More Step Forward
n Understanding Its Role*
auro Moscucci, MD, Noah Jones, MD, MPH
nn Arbor, Michigan
pidemiologic studies have shown that up to 60% of
atients with peripheral arterial disease have underlying
linical or subclinical coronary artery disease (1) and that the
resence of peripheral arterial disease is associated with a
.6-fold increase in relative risk of death from coronary
eart disease (2). In addition to this strong relationship
etween peripheral arterial disease and cardiovascular mor-
ality, numerous studies have shown a high risk of morbidity
nd mortality in patients with peripheral arterial disease
ndergoing surgical procedures, and in particular in patients
ndergoing open vascular surgical procedures. Angina pec-
oris, prior myocardial infarction (MI), prior heart failure,
evere renal insufficiency, poor functional capacity (3,4),
evere valvular heart disease, and myocardial ischemia on
on-invasive testing are today recognized markers for in-
reased risk (3). Although over the past 2 decades we have
earned how to identify patients with peripheral arterial
isease at increased risk of complication following surgical
rocedures, effective interventions aimed toward reducing
uch risk remain somewhat elusive.
See page 1763
Aggressive medical management and myocardial protec-
ion with beta-blockers, statins, and antiplatelet agents
urrently play key roles in the perioperative management of
atients undergoing vascular surgery (5–7). In particular, the
se of beta-blockers in the perioperative state has been
ound to be associated with a significant reduction in the
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agle, MD, acted as the Guest Editor for this article.ncidence of perioperative ischemia, nonfatal MI, and death
rom cardiac cause (5) and with a lower mortality at short-
nd long-term follow-up following the index procedure (6).
The role of preoperative coronary revascularization in this
atient population has been in part clarified by the recent
ARP (Coronary Artery Revascularization Prophylaxis)
rial (8). In the CARP trial, patients with stable coronary
rtery disease scheduled to undergo elective vascular oper-
tions were randomized to coronary revascularization or to
ptimal medical therapy. Medical therapy was optimized in
oth groups. Patients with left main stenosis 50%, left
entricular ejection fraction 20%, and severe aortic steno-
is were excluded. The majority of patients enrolled had
ingle- or 2-vessel disease. Following vascular surgery, there
ere no differences between the 2 groups in the incidence of
I or in-hospital mortality. At a median follow-up time of
.7 years, the mortality rate was 22% in the revascularization
roup and 23% in the no-revascularization group. A non-
ignificant trend toward a benefit of revascularization was
dentified in a small group of high-risk patients. Thus,
lthough underpowered to detect differences in event rates
n high-risk subgroups, the CARP trial suggested that if
ascular surgery candidates are carefully screened and pa-
ients with unstable coronary symptoms, left main disease,
ortic stenosis, or severe left ventricular dysfunction are
xcluded, revascularization does not appear to provide ad-
itional benefit in reducing the incidence of perioperative
eath or MI when compared with optimal perioperative
edical treatment (9). Thus, the CARP trial provided us
ith an answer to the critical question regarding revascu-
arization therapy, but left unsettled the questions regarding
creening of patients and revascularization in high-risk
atients.
In this issue of the Journal, Poldermans et al. (10) report
he result of the DECREASE (Dutch Echocardiographic
ardiac Risk Evaluation Applying Stress Echo Study
roup)-V pilot study, a small randomized pilot study designed
o test the safety and efficacy of 2 different treatment strategies
n patients undergoing major vascular surgery. The population
ncluded patients scheduled to undergo abdominal aortic an-
urysm repair or infrainguinal peripheral bypass surgery. Pa-
ients with 3 or more cardiovascular risk factors were evaluated
ith either dobutamine stress echocardiography or stress nu-
lear imaging. Those with extensive stress-induced ischemia
ere then randomized to either cardiac catheterization fol-
owed by coronary revascularization (percutaneous coronary
ntervention or coronary artery bypass grafting) or to medical
herapy. All patients received beta-blockers, and anti-platelet
herapy was continued in the perioperative period. The primary
nd point was a composite all-cause mortality and nonfatal MI
t 30 days, and the secondary end point was a composite
ll-cause mortality and nonfatal MI at 1 year. A total of 1,880
atients were screened and, of these, 430 patients were iden-
ified has being at high risk (3 risk factors). Of the 430
igh-risk patients, 101 (23%) showed extensive ischemia and
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May 1, 2007:1770–1 Editorial Commentere randomly assigned to revascularization (n  49) or no
evascularization (n  52). At 30-day follow-up, the inci-
ence of the composite end point was 43% and 33% in the
evascularization and no-revascularization group, respec-
ively (odds ratio [OR] 1.4, 95% confidence interval [CI]
.7 to 2.8, p  0.30). No benefit with revascularization was
bserved at 1-year follow-up (event rates 49% vs. 44%, OR
.2, 95% CI 0.7 to 2.3, p  0.48). Importantly, 2 patients
ied after revascularization but before the operation because
f a ruptured aneurysm.
The results of this study should be evaluated taking into
ccount several factors. First, as stated by the authors in
heir introduction, the purpose of the study was “to assess
he feasibility, and to obtain initial efficacy and safety
stimates for the design of an adequately powered random-
zed controlled clinical trial in these patients.” Thus, the
rial was not powered to show a difference between optimal
edical therapy and revascularization in high-risk patients.
n the basis of the results obtained in this pilot study, the
uthors estimate that it would be safe to design such trials,
nd that in order to show that coronary revascularization is
uperior to medical therapy in improving postoperative
utcome in high-risk patients by 20% (relative risk), more
han 300 patients per arm would be required. Such a sample
ize would also require screening 9,000 major vascular
urgery patients, of whom 2,000 would have 3 or more
ardiac risk factors at screening. In addition, in the CARP
rial, there was a nonsignificant trend toward a benefit of
evascularization in a small group of patients with high-risk
linical features and objective evidence of ischemia (adjusted
R 4.0, 95% CI 0.8 to 19). In contrast, no such trend was
bserved in the current study, which specifically addressed
igh-risk patients. All this taken into account, the equiva-
ence between medical therapy alone and revascularization
lus medical therapy in high-risk patients is far from being
roven.
Second, although the CARP trial addressed the issue of
reatment following screening, in the current study, patients
ho were already identified as high risk were randomized to
n invasive approach plus revascularization and optimal
edical therapy versus optimal medical therapy alone. None
f the patients randomized to optimal medical therapy alone
nderwent diagnostic cardiac catheterization, thus suggest-
ng that effective beta-blockade and medical therapy might
e sufficient and raising the question whether stable patients
cheduled for major vascular surgery should even be
creened with stress testing.
Third, 2 patients in the revascularization group died after
evascularization but before operation because of a ruptured
neurysm, consistent with the fact that urgent or emergency
ascular surgery in unstable patients should not be delayed
y revascularization.
Finally, despite full optimization of medical therapy, thevent rate in both treatment groups was still very high,aising the additional question of how we can further reduce
dverse events in these high-risk patients.
The lack of benefit from revascularization in the periop-
rative period observed both in this trial and in the CARP
rial can be reconciled on the basis of histopathologic
tudies, which have shown that the pathophysiology sur-
ounding fatal MI in the perioperative period after non-
ardiac surgery often includes unstable plaque and plaque
isruption (11). Thus, it is possible that revascularization of
table coronary artery stenosis might not add significantly to
he effect of optimal medical therapy, similar to what has
een shown for other low-risk patients with stable coronary
rtery disease.
All that said, the debate on screening and revasculariza-
ion for patients with peripheral arterial disease and sched-
led for major vascular surgery continues to be far from
ettled. The importance of the DECREASE-V pilot trial is
hat it provides us with supporting evidence on safety and
ith the needed sample size for a larger trial that could help
n settling this issue. It is now time to move forward with
uch a trial.
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